Abstract The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes
That said, some people do successfully transition off Ozempic while maintaining some benefits
This transparent, predictable model ensures you can afford to start low and titrate gradually as your post-cholecystectomy system adapts
References Abdelkader NF, Elbaset MA, Moustafa PE, Ibrahim SM (2022) Empagliflozin mitigates type 2 diabetes-associated peripheral neuropathy: a glucose-independent effect through AMPK signaling
What to do when side effects will not go away For the 5 to 10% of people who experience persistent side effects beyond the typical adaptation period, there are several strategies worth discussing with a healthcare provider